The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Does GLP-1RA use impact the risk of thyroid cancer? GLP-1RAs are highly effective medications used to treat T2D and obesity while simultaneously conferring protection against cardiovascular ...

Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of discontinuation by 3.1% in patients with type 2 diabetes and 3.3% in those without.

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) asset MET-097i through a Phase III trial.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

Efruxifermin (EFX) with GLP-1RA significantly reduces hepatic fat fraction and improves fibrosis in MASH and T2D patients. The study involved 31 patients over 12 weeks, showing EFX enhances GLP ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...

Overall, with median follow-up times of 660 days (range, 254-1157 days) in the GLP-1 RA group; approximately 4 years in the sulfonylurea and DPP-4 inhibitor groups; and about 2.5 years in the ...

Cochran Veterans Hospital in St. Louis. “Our approach has allowed us to build a comprehensive atlas mapping the associations of GLP-1RA spanning all organ systems,” he said. “The study’s ...